How Monte Rosa's MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE's Risk-Reward Profile [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
enzalutamide, was well-tolerated and produced positive clinical responses in heavily pretreated metastatic castration-resistant prostate cancer patients, and outlined plans to advance the program into Phase 2 and eventual registrational studies. This progress highlights Monte Rosa's effort to translate its molecular glue degrader platform into a potential new treatment option for advanced, mutation-driven prostate cancer. We'll now examine how these MRT-2359 prostate cancer data and the company's funding plans shape Monte Rosa Therapeutics' broader investment narrative. Uncover the next big thing with 31 elite penny stocks that balance risk and reward. What Is Monte Rosa Therapeutics' Investment Narrative? To own Monte Rosa Therapeutics, you need to believe its molecular glue degrader platform can convert promising early data into approved drugs before funding and execution risks bite. The updated MRT-2359 prostate cancer results strengthen the scientific story and, in the n
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)GlobeNewswire
- Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains [Yahoo! Finance]Yahoo! Finance
GLUE
Sec Filings
- 3/5/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 144
- GLUE's page on the SEC website